Parallax Health Sciences

Parallax Health Sciences developed and commercialized a connected telehealth and remote patient monitoring platform (Good Health Outcomes) and owned Parallax Diagnostics, which commercialized an FDA‑cleared point‑of‑care immunoassay platform (Target System VT1000) with 26 approved tests across infectious disease, cardiac, medical conditions, drugs of abuse, and pregnancy; there is no evidence of therapeutic drug products or clinical‑stage drug trials, and the company later faced SEC enforcement over misleading COVID‑19 test and PPE claims, with trading in its stock suspended and the business effectively inactive/insolvent by 2020–2021.[1][4][6][8]